NORTH CHICAGO, Ill.,
March 15, 2022 /PRNewswire/ -- AbbVie
(NYSE: ABBV) and Scripps Research, an independent, non-profit
biomedical research and drug discovery institute, today announced a
global collaboration to develop potential novel, direct-acting
antiviral treatments for COVID-19.
"Constant change is something we've experienced throughout the
COVID-19 pandemic, with the emergence of many new variants and the
evolving needs of treatment options to combat more contagious,
aggressive and severe strains of the virus," said Tom Hudson, M.D., senior vice president,
R&D, chief scientific officer, AbbVie. "We are committed to
bringing differentiated, next generation oral antiviral treatments
to patients and ensuring broad access to address the diverse
treatment needs around the world."
The initial SARS-CoV-2 research program at Calibr, the drug
discovery and development division of Scripps Research, was
supported by funding from the Bill & Melinda Gates
Foundation.
"We believe our SARS-CoV-2 research program has the potential to
impact significantly the ongoing gaps in patient needs to move from
pandemic to endemic COVID-19," said Peter
Schultz, Ph.D., president and chief executive officer,
Scripps Research. "We are excited to partner with AbbVie who brings
both the scientific expertise and the manufacturing capabilities to
accelerate the development of this program."
Closing of the transaction remains subject to satisfaction of
customary closing conditions, including applicable regulatory
approvals.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women's health and gastroenterology, in addition to products and
services across its Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, Instagram, YouTube and
LinkedIn.
For more information about AbbVie's COVID-19 research and
discovery efforts, visit
https://www.abbvie.com/our-science/covid-19-research-development.html.
About Scripps Research
Scripps Research is an
independent, nonprofit research institute ranked the #1 stand-alone
biomedical research institute in the US. Our drug discovery and
development division, Calibr, works hand-in-hand with scientists
across disciplines to accelerate the delivery of innovative, new
medicines to patients for a host of diseases. Scripps Research also
trains the next generation of scientists at our Skaggs Graduate
School, consistently named among the top 10 US programs for
chemistry and biological sciences. Learn more at
www.scripps.edu.
Forward-Looking Statements
Some statements in this
news release are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "anticipate," "project" and
similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, failure to realize
the expected benefits from AbbVie's acquisition of Allergan plc
("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2021 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
View original
content:https://www.prnewswire.com/news-releases/abbvie-and-scripps-research-announce-collaboration-to-develop-antiviral-treatments-for-covid-19-301502525.html
SOURCE AbbVie